Prescription of antidepressants is increased in Danish patients with polycystic ovary syndrome and is associated with hyperandrogenism. A population‐based cohort study. (5th December 2013)

• Record Type: Journal Article
• Authors: Altinok, M. L.; Glintborg, D.; dePont Christensen, R.; Hallas, J.; Andersen, M.
• Is Part Of: Clinical endocrinology. Volume 80:Number 6(2014:Jun.)
• Page Start: 884
• Page End: 889
• Publication Date: 2013-12-05
• Subjects: Endocrinology -- Periodicals; 616.4005
• DOI: 10.1111/cen.12365
• Languages: English
• ISSNs: 0300-0664

Abstract

<abstract abstract-type="main" id="cen12365-abs-0001"> <title>Summary</title> <sec id="cen12365-sec-0001" sec-type="section"> <title>Objective</title> <p>Quality of life is impaired in polycystic ovary syndrome (PCOS). In this study, we compared the time to first prescription of antidepressants (ADM) in PCOS <italic>vs</italic> two control groups.</p> </sec> <sec id="cen12365-sec-0002" sec-type="section"> <title>Design</title> <p>Register‐based cohort study.</p> </sec> <sec id="cen12365-sec-0003" sec-type="section"> <title>Patients</title> <p>One thousand and one hundred and twenty‐four premenopausal women with hirsutism and/or PCOS, premenopausal women with hypertension (HT, <italic> n</italic> = 301), and age‐ and sex‐matched population controls (controls, <italic>n</italic> = 4110).</p> </sec> <sec id="cen12365-sec-0004" sec-type="section"> <title>Measurements</title> <p>Prescriptions for ADM on secondary care contacts from regional registers.</p> </sec> <sec id="cen12365-sec-0005" sec-type="section"> <title>Results</title> <p>The median age at cohort entry in PCOS, HT and controls was 29, 34 and 29 years, respectively. Among PCOS, HT and controls, 227 (20%), 74 (25%) and 633 (15%), respectively, had prescriptions of ADM. The median time to first prescription of ADM in the PCOS, HT and control cohorts was 6·8, 6·6 and 7·2 years, respectively. The adjusted hazard ratio for time to prescription of ADM for HT <italic>vs</italic> PCOS was 1·36 [95% CI (1·02–1·82)], <italic>P</italic> = 0·039, and for controls <italic>vs</italic> PCOS, it was 0·75 [95% CI (0·64–0·88)], <italic>P</italic> < 0·001. Within patients with PCOS, hyperandrogenism contributed significantly to the model, likelihood ratio test <italic>P</italic> = 0·009. The adjusted hazard ratio for hyperandrogenism <italic>vs</italic> no hyperandrogenism was 1·97 (1·12–3·45), <italic>P</italic> = 0·018.</p> </sec> <sec id="cen12365-sec-0006" sec-type="section"> <title>Conclusion</title> <p>Patients with PCOS had moderately but significantly decreased time to first prescription of ADM compared with age‐matched healthy women, whereas patients with HT had the shortest time to prescription. In PCOS, prescription of ADM was associated with the presence of hyperandrogenism.</p> </sec> </abstract>